Latest & greatest articles for sitagliptin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sitagliptin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sitagliptin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sitagliptin

62. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Schwarz B, Gouveia M (...) , Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of adding sitagliptin to treatment for patients

NHS Economic Evaluation Database.2008

64. Janumet (Sitagliptin/Metformin Hydrochloride)

Janumet (Sitagliptin/Metformin Hydrochloride) Drug Approval Package: Janumet (Sitagliptin/Metformin Hydrochloride) NDA #022044 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Janumet (Sitagliptin/Metformin Hydrochloride) Tablets Company: Merck & Co., Inc. Application No.: 022044 Approval Date: 03/30/2007 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 8, 2008 Note: Documents in PDF

FDA - Drug Approval Package2007

67. Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review

Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review (...) . Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to assess the effectiveness of sitagliptin (MK 0431) for type 2 diabetes. Authors' conclusions Sitagliptin (MK 0431) belongs to the new class of incretin enhancer drugs that also includes LAF237 (Vildagliptin) and exenatide. Sitagliptin is administered orally and is in clinical trials in addition to, and as a substitute for, current glucose-lowering therapies in patients with type 2 diabetes. Phase II clinical

Health Technology Assessment (HTA) Database.2005